Physician profile
Denise Schultz
NPI 1306060454
$15,026.54
in general payments reported to CMS, 2019-2025
62 companies · $2,648 in 2025
The $2,648 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,227 · 2022: $3,464 · 2023: $2,811 · 2024: $2,876 · 2025: $2,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,334.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,076.93 | 2021-2025 | |
| Ucb, INC. | $944.17 | 2022-2025 | Nayzilam, Briviact, Rystiggo |
| Lilly USA, LLC | $767.93 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Sk Life Science, INC. | $754.76 | 2021-2025 | |
| Kyowa Kirin, INC. | $715.33 | 2021-2025 | Nourianz |
| Eisai INC. | $703.21 | 2021-2025 | |
| Pfizer INC. | $542.32 | 2021-2025 | |
| Emd Serono, INC. | $440.67 | 2022-2025 | Mavenclad |
| Allergan, INC. | $320.82 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $299.63 | 2021 | |
| Sumitomo Pharma America, INC. | $290.39 | 2023-2024 | Aptiom |
| Lundbeck LLC | $278.04 | 2021-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $255.76 | 2023-2025 | Rytary, Crexont |
| Otsuka America Pharmaceutical, INC. | $242.15 | 2023-2025 | Rexulti |
| Biogen, INC. | $226.65 | 2021-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.